Pictet Asset Management Holding SA Has $27.47 Million Stock Holdings in Edwards Lifesciences Corporation $EW

Pictet Asset Management Holding SA decreased its position in Edwards Lifesciences Corporation (NYSE:EW) by 2.6% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 343,016 shares of the medical research company’s stock after selling 9,200 shares during the period. Pictet Asset Management Holding SA’s holdings in Edwards Lifesciences were worth $27,469,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of EW. MV Capital Management Inc. bought a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $26,000. Hanson & Doremus Investment Management acquired a new position in Edwards Lifesciences during the first quarter worth $25,000. Kemnay Advisory Services Inc. acquired a new position in Edwards Lifesciences during the fourth quarter worth $27,000. JPL Wealth Management LLC bought a new position in Edwards Lifesciences in the third quarter valued at $25,000. Finally, Hilton Head Capital Partners LLC bought a new position in Edwards Lifesciences in the fourth quarter valued at $28,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $91.95 on Thursday. The company has a fifty day moving average price of $85.06 and a two-hundred day moving average price of $83.41. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $92.88. The stock has a market cap of $52.95 billion, a P/E ratio of 48.91, a P/E/G ratio of 2.27 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.05. The company had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. Edwards Lifesciences’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insiders Place Their Bets

In other news, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the transaction, the senior vice president directly owned 15,334 shares in the company, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $83.01, for a total value of $84,587.19. Following the transaction, the vice president directly owned 33,934 shares in the company, valued at $2,816,861.34. The trade was a 2.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 58,977 shares of company stock worth $4,921,803 in the last three months. 0.31% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on EW shares. Wolfe Research raised shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price target on the stock in a research report on Wednesday, April 1st. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday, April 20th. TD Cowen reaffirmed a “buy” rating and issued a $104.00 target price (up from $97.00) on shares of Edwards Lifesciences in a research report on Tuesday, June 2nd. Truist Financial set a $90.00 target price on Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $100.00 price target on shares of Edwards Lifesciences in a research report on Tuesday, June 16th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $96.39.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.